TY - JOUR
T1 - Spinal Cord Stimulation for Failed Back Surgery Syndrome
T2 - to Trial or Not to Trial?
AU - Witkam, Richard L.
AU - Kragt, Elisabeth A. M.
AU - Arnts, Inge J. J.
AU - Bronkhorst, Ewald M.
AU - van Dongen, Robert
AU - Kurt, Erkan
AU - Steegers, Monique A. H.
AU - van Haren, Frank G. A. M.
AU - Maandag, Natasja J. G.
AU - Gort, Cees
AU - Henssen, Dylan J. H. A.
AU - Wegener, Jessica T.
AU - Vissers, Kris C. P.
N1 - Funding Information:
No funding was received for conducting this research.
Publisher Copyright:
© 2023 The Authors
PY - 2023
Y1 - 2023
N2 - Spinal cord stimulation (SCS) is a recommended therapy to treat failed back surgery syndrome (FBSS). A trial period is practiced to enhance patient selection. However, its fundamental evidence is limited, especially concerning long-term benefit and therapy safety. We compared the long-term (5.3 ± 4.0 years) clinical outcome and therapy safety of a trialed and nontrialed implantation strategy, including multidimensional variables and pain intensity fluctuations over time. A multicenter cohort analysis was performed in 2 comparable groups of FBSS patients. Regarding eligibility, patients had to be treated with SCS for at least 3 months. While the Trial group comprised patients who underwent an SCS implantation after a successful trial, the No-Trial group encompassed patients who underwent complete implantation within 1 session. The primary outcome measures were pain intensity scores and complications. The Trial and No-Trial groups consisted of 194 and 376 patients (N = 570), respectively. A statistically but not clinically significant difference in pain intensity (P =.003; effect = 0.506 (.172–.839)) was found in favor of the Trial group. No interaction between a time dependency effect and pain intensity was noted. Whereas trialed SCS patients were more likely to cease opioid usage (P =.003; OR =.509 (.326–.792)), patients in the No-Trial group endured fewer infections (P =.006; proportion difference =.43 (.007–.083)). Although the clinical relevance of our findings should be proven in future studies, this long-term real-world data study indicates that patient-centered assessments on whether an SCS trial should be performed have to be investigated. According to the current ambiguous evidence, SCS trials should be considered on a case-by-case basis. Perspective: The currently available comparative evidence, together with our results, remains ambiguous on which SCS implantation strategy might be deemed superior. An SCS trial should be considered on a case-by-case basis, for which further investigation of its clinical utility in certain patient populations or character traits is warranted.
AB - Spinal cord stimulation (SCS) is a recommended therapy to treat failed back surgery syndrome (FBSS). A trial period is practiced to enhance patient selection. However, its fundamental evidence is limited, especially concerning long-term benefit and therapy safety. We compared the long-term (5.3 ± 4.0 years) clinical outcome and therapy safety of a trialed and nontrialed implantation strategy, including multidimensional variables and pain intensity fluctuations over time. A multicenter cohort analysis was performed in 2 comparable groups of FBSS patients. Regarding eligibility, patients had to be treated with SCS for at least 3 months. While the Trial group comprised patients who underwent an SCS implantation after a successful trial, the No-Trial group encompassed patients who underwent complete implantation within 1 session. The primary outcome measures were pain intensity scores and complications. The Trial and No-Trial groups consisted of 194 and 376 patients (N = 570), respectively. A statistically but not clinically significant difference in pain intensity (P =.003; effect = 0.506 (.172–.839)) was found in favor of the Trial group. No interaction between a time dependency effect and pain intensity was noted. Whereas trialed SCS patients were more likely to cease opioid usage (P =.003; OR =.509 (.326–.792)), patients in the No-Trial group endured fewer infections (P =.006; proportion difference =.43 (.007–.083)). Although the clinical relevance of our findings should be proven in future studies, this long-term real-world data study indicates that patient-centered assessments on whether an SCS trial should be performed have to be investigated. According to the current ambiguous evidence, SCS trials should be considered on a case-by-case basis. Perspective: The currently available comparative evidence, together with our results, remains ambiguous on which SCS implantation strategy might be deemed superior. An SCS trial should be considered on a case-by-case basis, for which further investigation of its clinical utility in certain patient populations or character traits is warranted.
KW - Complications
KW - Failed back surgery syndrome
KW - Long-term follow-up
KW - Medication intake
KW - Multidimensional outcomes
KW - Pain Intensity
KW - Screening trial
KW - Spinal cord stimulation
KW - Therapy safety
KW - Trial period
UR - http://www.scopus.com/inward/record.url?scp=85153954982&partnerID=8YFLogxK
U2 - 10.1016/j.jpain.2023.02.032
DO - 10.1016/j.jpain.2023.02.032
M3 - Article
C2 - 36878384
SN - 1526-5900
JO - Journal of Pain
JF - Journal of Pain
ER -